No Data
Zhejiang CONBA Pharmaceutical Gets Registration Approval for Asthma Relief Drug
Express News | Zhejiang Conba Pharmaceutical: Subsidiary Jinhua Conba Pharmaceutical has obtained the registration certificate for the inhalation solution of ipratropium bromide.
Zhejiang Conba Pharmaceutical (600572.SH): The subsidiary has obtained a pharmaceutical registration certificate for inhaled ipratropium bromide solution.
On January 16, Gelonghui reported that Zhejiang Conba Pharmaceutical (600572.SH) announced that its wholly-owned subsidiary, Zhejiang Jinhua Conba Pharmaceutical Co., Ltd., received the Drug Registration Certificate approved by the National Medical Products Administration for a 2ml: 0.5mg inhalation solution of ipratropium bromide. The inhalation solution of ipratropium bromide was originally developed by Boehringer Ingelheim and launched in the United Kingdom in 1986, and received approval for marketing in China in 2006. As a bronchodilator, the inhalation solution of ipratropium bromide is used for the maintenance treatment of bronchospasm caused by chronic obstructive pulmonary disease.
Express News | Zhejiang Conba Pharmaceutical: Subsidiary Entecavir Tablets have been approved by the FDA in the USA.
Zhejiang Conba Pharmaceutical (600572.SH) appointed Chairman Jiang Yi to also serve as the company's President.
Zhejiang Conba Pharmaceutical (600572.SH) announced that the company's Board of Directors recently received a submission from the company's president, Mr. Luo Guoliang...
Express News | Zhejiang Conba Pharmaceutical: The amikacin sulfate injection is expected to win the bid in the tenth batch of national pharmaceutical collective procurement.
